2013
DOI: 10.1016/j.jconrel.2013.01.002
|View full text |Cite
|
Sign up to set email alerts
|

A hydrogel composite system for sustained epi-cortical delivery of Cyclosporin A to the brain for treatment of stroke

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
48
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
6
2

Relationship

5
3

Authors

Journals

citations
Cited by 71 publications
(50 citation statements)
references
References 28 publications
1
48
0
Order By: Relevance
“…CsA (Cat.# C-6000, LC Laboratories, Woburn, MA, USA) was encapsulated in PLGA (acid-terminated 50:50, MW 7,000-17,000, Cat.# 71989) microparticles using a singlephase oil/water emulsion solvent evaporation technique, as described previously [15]. Blank PLGA particles were similarly prepared without the addition of CsA in the organic phase.…”
Section: Csa Encapsulation In Plga Microparticlesmentioning
confidence: 99%
See 1 more Smart Citation
“…CsA (Cat.# C-6000, LC Laboratories, Woburn, MA, USA) was encapsulated in PLGA (acid-terminated 50:50, MW 7,000-17,000, Cat.# 71989) microparticles using a singlephase oil/water emulsion solvent evaporation technique, as described previously [15]. Blank PLGA particles were similarly prepared without the addition of CsA in the organic phase.…”
Section: Csa Encapsulation In Plga Microparticlesmentioning
confidence: 99%
“…It is injectable, gels rapidly at physiological temperatures, and is bioresorbable [9]. HAMC can be used alone [10][11][12][13] or in combination with drug-loaded polymeric particles [7,14,15] to deliver therapeutics to the CNS. In the mouse brain, an epi-cortical delivery strategy was used to inject HAMC for local drug release of bioactive drug without damage to brain tissue [7,12,13,15] (Fig.…”
Section: Introductionmentioning
confidence: 99%
“…Phase 2 clinical trials are ongoing for a combination of bolus injection and continuous infusion after TBI (CHIC, NCT01825044) or a single bolus injection after stroke (CsAStroke, NCT01527240). Although these efforts may be plagued by off-target side effects of immune suppression seen with corticosteroids, future success may be seen with nonimmunosuppressant analogues targeting antiapoptotic pathways (e.g., NIM811 [64]) or local delivery methods that avoid off-target effects [65].…”
Section: Clinical Trials In the Brainmentioning
confidence: 99%
“…Alternatively, a variety of sustained-release strategies could be employed. Cyclosporine A, a potent anti-inflammatory drug, has been incorporated into PLGA microspheres or HA-methylcellulose composites as drug reservoirs and slowly released over the brain cortex [95]. PLGA particles have been further used to deliver dexamethasone, another potent immunosuppressor, to the CNS [96].…”
Section: Trophic Support and Protection From Inflammationmentioning
confidence: 99%